Who makes Baxdela?
1. Melinta Therapeutics. BAXDELA (delafloxacin): US Prescribing Information. 2017.
Who makes delafloxacin?
History. Delafloxacin was known as ABT-492, RX-3341, and WQ-3034 while it was under development. Rib-X Pharmaceuticals acquired delafloxacin from Wakunaga Pharmaceutical in 2006. Rib-X was renamed to Melinta Therapeutics in 2013.
How much does Baxdela cost?
The cost for Baxdela oral tablet 450 mg is around $1,502 for a supply of 20 tablets, depending on the pharmacy you visit.
What does Baxdela treat?
BAXDELA® is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by designated susceptible bacteria.
Is delafloxacin available in the US?
Delafloxacin (BaxdelaTM), a novel anionic FQ, was approved by the FDA on June 19th, 2017 for the indication of acute bacterial skin and skin structure infections (ABSSSI). So, another FQ gains US FDA approval.
How is delafloxacin different from other fluoroquinolones?
The most recently approved class member, delafloxacin, is the only available anionic (non-zwitterionic) fluoroquinolone. Its unique molecular structure provides improved in vitro activity against most Gram-positive pathogens, including quinolone-resistant strains, which is further enhanced at acid pH.
Is delafloxacin a respiratory fluoroquinolone?
Delafloxacin is a novel fluoroquinolone with activity against Gram-positive, Gram-negative, and atypical pathogens, including fluoroquinolone-nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA).
Is factive discontinued?
FACTIVE was discontinued because of an adverse reactions in 2.0% of patients, primarily due to rash (0.8%), nausea (0.3%), diarrhea (0.3%), urticaria (0.2%) and vomiting (0.2%).